MarketInOut Stock Screener Log In | Sign Up
 

BridgeBio Oncology Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/16/2026 16:00
BridgeBio Oncology Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization261.37 mln
Float47.85 mln
Earnings Date11/18/2026

Piotroski F-Score

1 / 9
Very weak

1-Year Forecast

24.55
Transformational upside

Relative Strength

8 / 100
Severely lagging

Debt / Equity

0.01
Debt-free

ROE

-52.26
Deeply negative

ROA

-47.29
Deeply negative

Business Description

BridgeBio Oncology Therapeutics is a clinical-stage biotech company focused on developing oral drug treatments for several types of cancer, including lung, breast, and colorectal cancers. The company is advancing multiple drug candidates through early-stage clinical trials, each designed to target specific genetic mutations that drive tumor growth. Founded in 2016 and based in South San Francisco, California, BridgeBio Oncology aims to deliver more precise treatment options for cancer patients with limited alternatives.

Key Fundamentals

EPS-0.07
ROE-52.26
ROIC-188
ROA-47.29
EBITDA, mln-181
EV / EBITDA2.79
EV / EBIT2.77

Quote Details

Last 2.82
Change -0.13 (-4.41%)
Open 2.95
Volume 480,748
Turnover 1,355,709
Average Volume 578,556

Financial Ratios

Leverage Ratio1.17
Current Ratio4.69
Price / Book1.01
Price / Tangible Book1.01
Debt / Equity0.01

Financial Strength

Piotroski F-Score 1 / 9
1-Year Target Price24.55
Short Ratio4.72
Short % of Float11.82

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -14.8% 14 / 100   
1 Month -42.33% 5 / 100   
2 Months -66.9% 4 / 100   
6 Months -69.84% 6 / 100   
1 Year -76.4% 10 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us